Plasma adiponectin, visfatin, leptin, and resistin levels and the onset of colonic polyps in patients with prediabetes.
Adenomatous Polyps
/ blood
Adiponectin
/ blood
Adult
Aged
Case-Control Studies
China
/ epidemiology
Colonic Polyps
/ blood
Colonoscopy
Colorectal Neoplasms
/ blood
Cytokines
/ blood
Female
Humans
Leptin
/ blood
Male
Middle Aged
Neoplasms, Multiple Primary
/ blood
Nicotinamide Phosphoribosyltransferase
/ blood
Prediabetic State
/ blood
Resistin
/ blood
Risk Factors
Adipokine
Colonic polyps
Prediabetes
Risk factors
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
11 May 2020
11 May 2020
Historique:
received:
22
03
2019
accepted:
28
04
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
17
3
2021
Statut:
epublish
Résumé
Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects. A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed. Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects.
Sections du résumé
BACKGROUND
BACKGROUND
Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects.
METHODS
METHODS
A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed.
RESULTS
RESULTS
Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects.
CONCLUSIONS
CONCLUSIONS
Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects.
Identifiants
pubmed: 32393372
doi: 10.1186/s12902-020-0540-7
pii: 10.1186/s12902-020-0540-7
pmc: PMC7216429
doi:
Substances chimiques
ADIPOQ protein, human
0
Adiponectin
0
Cytokines
0
LEP protein, human
0
Leptin
0
RETN protein, human
0
Resistin
0
Nicotinamide Phosphoribosyltransferase
EC 2.4.2.12
nicotinamide phosphoribosyltransferase, human
EC 2.4.2.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Subventions
Organisme : Natural Science Foundation of Anhui Province
ID : 1508085MH150
Organisme : the Chinese Medical Association Clinical Special Fund
ID : 12020320320322
Références
Gastroenterology. 2008 May;134(5):1570-95
pubmed: 18384785
JAMA. 2003 Dec 10;290(22):2959-67
pubmed: 14665657
J Clin Endocrinol Metab. 2008 Sep;93(9):3259-65
pubmed: 18772457
Diabetologia. 2010 Sep;53(9):1867-76
pubmed: 20490448
Recent Results Cancer Res. 2016;208:17-41
pubmed: 27909900
Nephron Clin Pract. 2011;118(4):c315-8
pubmed: 21293153
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Dig Dis Sci. 2013 Jul;58(7):2061-7
pubmed: 23423502
Int J Colorectal Dis. 2009 Mar;24(3):275-81
pubmed: 18979105
Biosci Rep. 2017 Dec 12;37(6):
pubmed: 29026008
Med Oncol. 2012 Dec;29(5):3129-35
pubmed: 22752603
Gut. 2008 Nov;57(11):1531-8
pubmed: 18676419
Crit Rev Oncol Hematol. 2017 Aug;116:125-133
pubmed: 28693794
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1449-1455
pubmed: 31336505
PLoS One. 2014 Jan 17;9(1):e85939
pubmed: 24465801
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3756-3764
pubmed: 28973588
Curr Nutr Rep. 2013 Mar;2(1):1-9
pubmed: 23396857
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1543-6
pubmed: 17684126
Front Biosci (Elite Ed). 2013 Jan 01;5:61-77
pubmed: 23276970
Asia Pac J Clin Oncol. 2016 Mar;12(1):e65-74
pubmed: 23910020
Asian Pac J Cancer Prev. 2014;15(1):397-405
pubmed: 24528064
Atherosclerosis. 2016 Dec;255:102-108
pubmed: 27870948
Acta Diabetol. 2018 Jul;55(7):741-749
pubmed: 29680968
J Cell Physiol. 2013 May;228(5):1017-24
pubmed: 23042611
Clin Colon Rectal Surg. 2009 Nov;22(4):191-7
pubmed: 21037809